CMV Seronegative Blood Components for Clinical Use Clinical Guideline
South Australian1 and national stewardship directives2, along with National Safety and Quality Health Service Standards3 (Standard 7) require Health Services to implement policies, procedures, guidelines and strategies to ensure safe and appropriate transfusion practice.
The CMV Seronegative Blood Components for Clinical Use Clinical Guideline (PDF 457KB) sets out the patient groups for whom transfusion with Cytomegalovirus (CMV) seronegative blood components/products is clinically indicated and supported by evidence, where available. It also establishes criteria for holding CMV seronegative blood components across SA Health based on the SA Health Clinical Services Capability Framework4.
There are significant logistics (and associated costs) in the provision of the limited supply of CMV-N products, over and above the supply of standard leucodepleted products. Although intended for use within SA Health, private hospitals and pathology providers should seek to adopt this guideline to ensure optimal clinical use of CMV-N products in South Australia.
Notes
- SA Health Blood Supply Stewardship Policy Directive, version 2.1. 20 Aug 2019.
- Australian Health Ministers’ Conference Statement on National Stewardship Expectations for the Supply of Blood and Blood Products. 12 Nov 2010
- Australian Commission on Safety and Quality in Health Care. National Safety and Quality Health Service Standards. 2nd ed. Sydney: ACSQHC; 2017
- SA Health. Clinical Services Capability Framework. Maternity and Neonatal Services. August 2016.